{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-043933","form_type":"8-K","ticker":"IMNN","cik":"0000749647","company_name":"Imunon, Inc.","filed_at":"2024-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:10.966996+00:00","generated_at":"2026-05-30T04:06:28.551398+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Imunon Q3 net loss $4.9M; progressing toward Phase 3 for IMNN-001 in ovarian cancer","bullets":["Net loss of $4.9M ($0.34 per share) vs $3.5M in Q3 2023; R&D expense $3.3M, G&A $1.7M.","Cash, investments of $10.3M; expects to fund operations into Q3 2025.","OVATION 2 topline: 11.1-month OS improvement, hazard ratio 0.74 in ITT; 15.7-month OS in per-protocol.","Plan 500-patient Phase 3 study start Q1 2025; End-of-Phase 2 FDA meeting later in November 2024.","Raised $10M gross proceeds in July 2024 registered direct offering; added General Counsel and SVP of Operations."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-043933","json":"https://secwatch.observer/filing/0001493152-24-043933.json","markdown":"https://secwatch.observer/filing/0001493152-24-043933.md","text":"https://secwatch.observer/filing/0001493152-24-043933.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/749647/000149315224043933/0001493152-24-043933-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/749647/000149315224043933/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T04:06:28.551398+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}